Slimming down is all the rage in health care these days. Pfizer
The company announced yesterday that it has sold Physio-Control to private-equity fund Bain Capital. The division, which is famous for its defibrillators but sells other emergency response products and services as well, contributed about $425 million to Medtronic's revenue annually over the past few years. All told, Medtronic is letting go of only about 2.5% of total sales.
At $487 million, Bain is paying just over 1.1 times sales for Physio-Control. Assuming Medtronic extracted the full value of the asset -- and it's not desperate for cash, so I imagine that's the case -- the ratio tells you Medtronic wasn't getting very good margins on Physio-Control's products. By contrast, investors are valuing Medtronic as a whole at 2.7 times sales over the past 12 months.
Medtronic says it'll use the cash to offset any dilutive impact of the lost revenue. The company doesn't break out earnings for individual units, but the loss isn't likely to make much of an impact on the bottom line. Medtronic would be best served using the cash to snatch up a new technology that could offer high growth and better margins in the future.
The sad part of selling off Physio-Control is that Medtronic originally purchased the unit back in 1998 for $538 million. Ironically, before it went public, Physio-Control was owned by Bain Capital, which originally bought the division from Eli Lilly
Unfortunately, sometimes diets cost money.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories and Medtronic. Motley Fool newsletter services have recommended buying shares of Pfizer and Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Stocks That Are Cash Cows
It's not just the cash. It's what these companies do with it that really matters.
Why 2017 Was a Year to Forget for Pfizer Inc.
Pfizer's 2017 wasn't horrible. Just ho-hum.
3 Dividend Stocks to Buy on Sale
It's hard to go wrong with high dividend yields, low earnings multiples, and solid long-term business prospects.